These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 17382156

  • 1. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV.
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR.
    Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 7. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.
    J Urol; 2001 Dec 01; 166(6):2193-7. PubMed ID: 11696734
    [Abstract] [Full Text] [Related]

  • 8. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH.
    J Clin Oncol; 2006 Sep 01; 24(25):4190-5. PubMed ID: 16943536
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH.
    J Urol; 2003 Apr 01; 169(4):1320-4. PubMed ID: 12629352
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb 01; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 12. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 13. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan 15; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.
    Br J Cancer; 2002 Sep 23; 87(7):726-8. PubMed ID: 12232754
    [Abstract] [Full Text] [Related]

  • 17. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 23; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK, Lee RJ, Snow G, Lee CM, Tward JD, Middleton AW, Middleton GW, Sause WT.
    Urology; 2007 Feb 23; 69(2):295-9. PubMed ID: 17320667
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R.
    J Urol; 2001 Sep 23; 166(3):851-5. PubMed ID: 11490232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.